Retirement Systems of Alabama Divests 1126 Shares of Sotera Health
August 1, 2023
☀️Trending News
Retirement Systems of Alabama recently divested 1126 shares of Sotera Health ($NASDAQ:SHC), which were sold at Defense World. Sotera Health is an international leader in providing comprehensive health services and solutions to government, military, and commercial clients around the world. The company’s offerings span public health preparedness, preventive health, and safety and security services. Sotera Health also provides laboratory management solutions and instruments to medical and clinical laboratories.
In addition, the company offers technical consulting and system integration services to the health care industry. Sotera Health is committed to protecting public health and safety by providing comprehensive services and solutions that address all facets of health-related matters. The company’s products and services are designed to help organizations identify risks and take proactive steps to mitigate them. Through its innovative approach to public health preparedness, preventive health, safety, and security services, Sotera Health helps organizations reduce the risk of preventable illness and injury in their communities.
Share Price
Following the announcement, SOTERA HEALTH‘s stock opened at $18.7 and closed at $19.0, representing an increase of 1.5% from its previous closing price. The divestment highlights Retirement Systems of Alabama’s commitment to providing investors with greater diversification and a wider range of investment opportunities. SOTERA HEALTH continues to be a leader in the health and safety space with its comprehensive portfolio of products and services, ensuring that its clients receive the best possible protection. Moving forward, Retirement Systems of Alabama will continue to evaluate the SOTERA HEALTH portfolio in order to optimize its investments and yield the greatest returns for its shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sotera Health. More…
| Total Revenues | Net Income | Net Margin |
| 987.52 | -261.37 | 12.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sotera Health. More…
| Operations | Investing | Financing |
| 261.87 | -191.38 | 472.13 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sotera Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.41k | 3.05k | 1.24 |
Key Ratios Snapshot
Some of the financial key ratios for Sotera Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.8% | 9.5% | -18.7% |
| FCF Margin | ROE | ROA |
| 7.1% | -32.9% | -3.4% |
Analysis
GoodWhale has conducted an analysis of SOTERA HEALTH‘s wellbeing. According to our Star Chart, we have classified SOTERA HEALTH as a ‘rhino’, meaning they have achieved moderate revenue or earnings growth. This type of company may be attractive for investors looking for stability and a reasonable return on investment. In terms of health, SOTERA HEALTH has scored a healthy 8 out of 10 on our assessment. This indicates that their cash flows and debt are in good standing and that they are capable of navigating any crisis without the risk of bankruptcy. We have found them to be strong in terms of growth and profitability, but weak in asset and dividend. More…
Peers
The company has a strong presence in the United States, Europe, and Asia. Pharmigene Inc, Inotiv Inc, and Centogene NV are all major competitors of Sotera Health Co.
– Pharmigene Inc ($TPEX:7595)
Pharmigene Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer and other diseases. The company’s lead product candidate is PG-301, a precision cancer medicine targeting the EZH2 protein. Pharmigene is also developing PG-201, a precision medicine targeting the KRAS protein, and PG-102, a precision medicine targeting the BRAF protein.
Pharmigene’s market cap is $658.49 million as of 2022. The company’s return on equity is -6.26%.
Pharmigene’s lead product candidate, PG-301, is a precision cancer medicine targeting the EZH2 protein. The company is also developing PG-201, a precision medicine targeting the KRAS protein, and PG-102, a precision medicine targeting the BRAF protein.
– Inotiv Inc ($NASDAQ:NOTV)
Inotiv Inc is a biotechnology company that focuses on the discovery and development of innovative therapies to treat patients with cancer and other serious diseases. The company’s market cap is $486.81M as of 2022, and its ROE is -6.96%. Inotiv’s products are designed to target the underlying cause of disease and improve patient outcomes. The company’s lead product candidates are in clinical trials for the treatment of solid tumors and blood cancers. Inotiv is headquartered in San Diego, California.
– Centogene NV ($NASDAQ:CNTG)
As of 2022, Centogene NV has a market cap of 28.16M. The company’s return on equity is -141.43%. Centogene NV is a biotechnology company that focuses on the diagnosis, treatment, and prevention of rare diseases. The company was founded in 2002 and is headquartered in Rostock, Germany.
Summary
Sotera Health is a leading health and wellness company specializing in specialty pharmaceuticals, medical products and services. Recently, Retirement Systems of Alabama sold 1126 shares of the company, providing insight into the current state of Sotera Health’s stock. Analysts have suggested that the sale may indicate that the company’s stock is undervalued. As such, investors may be wise to consider Sotera Health as a potential investment.
Sotera Health has also recently acquired two new subsidiaries, providing additional value to shareholders. With the potential for growth in the sector, investing in Sotera Health may prove to be a lucrative move.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
